Elite Pharmaceuticals, Inc. (ELTP)
Chart Events
Performance Outlook
| Previous Close | 0.0346 |
| Open | 0.0345 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0321 - 0.0375 |
| 52 Week Range | 0.0200 - 0.0600 |
| Volume | |
| Avg. Volume | 415,724 |
| Market Cap | 37.923M |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | 6.25 |
| EPS (TTM) | 0.0060 |
| Earnings Date | Aug 07, 2020 - Aug 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Robert Chen as Chief Financial Officer
NORTHVALE, NJ / ACCESSWIRE / May 11, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Robert Chen, CPA/MPA, as its Chief Financial Officer (CFO), effective May 16, 2022, succeeding Marc Bregman.
- ACCESSWIRE
Elite Pharmaceuticals and Praxgen Pharmaceuticals Receive FDA Approval for Generic Doxycycline
NORTHVALE, NJ / ACCESSWIRE / April 4, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that together with Elite's co-development partner, Praxgen Pharmaceuticals LLC, formerly SunGen Pharma LLC, ("Praxgen") received approval from the US Food and Drug Administration (FDA) for doxycycline hyclate 100 mg tablets.
- ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2021 and Provides Conference Call Information
Conference Call Scheduled for Tuesday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2022 ended December 31, 2021 ("Third Quarter").
